AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.

Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of lung cancer cases. The treatment plan and goal of treatment depend on the stage of your ...

Bladder cancer hopes back on track There was better ... after a new FDA approval in non-small cell lung cancer (NSCLC). In the age of AI, large data sets – like the treasure trove of customer ...

The recent GST cut on cancer drugs could mean significant cost reductions for cancer treatment in India. Read to know how it ...

Small cell bladder cancer (SCBC) is a rare histologic subtype with relative paucity of data regarding treatment response and outcomes. We reviewed 2 databases to compare outcomes in patients with ...

Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

From combining treatments in unprecedented ways to deploying artificial intelligence for personalized medicine, a raft of new ...